In addition, CpG ODNs are associated with the upregulation of indoleamine 2,3-dioxygenase (IDO) side-effects, and the enzymatic properties of IDO have been reported to inhibit T cell activation and promote Treg induction to the tumor milieu [3]. The gene discussed is IDO1; the disease is neoplasm.